The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Immuno-Oncology 2022 | Improving outcomes in NSCLC with perioperative targeted therapies
Si-Yang Liu, MD, Guangdong Lung Cancer Institute, Guangzhou, China, comments on the role of neoadjuvant therapy in non-small cell lung cancer (NSCLC). Neoadjuvant and adjuvant therapies are currently available for patients receiving surgery and neoadjuvant therapy can trigger immune responses in patients and shrink the tumor before surgery. Neoadjuvant therapy can additionally lower minimal residual disease (MRD) levels in patients, further enhancing outcomes. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
